
OneMedNet receives high‑six‑figure add‑on order for clinical AI data
An existing customer expands data volume by 150 per cent, but delivery timing and the exact contract value remain undisclosed.

The generator forecasts US$1.5B to US$1.75B in adjusted free cash flow for 2027 as acquired plants contribute a full year.

An existing customer expands data volume by 150 per cent, but delivery timing and the exact contract value remain undisclosed.

Collection succeeded in 94.7 per cent of patients, but the retrospective analysis measures feasibility rather than comparative cancer outcomes.
North American production incentives contributed 416.9 billion won as storage shipments grew and European plant utilization improved.
The Alaska program tested resource gaps and extensions with 50 to 100 metre step-outs; reported intervals are core lengths with true widths unknown.

Foremost receives C$650,000, retains 20 per cent of each property and issues five-year warrants to Denison with an ownership cap.

The non-brokered offering would add up to 8 million shares and 4 million warrants, with proceeds for exploration and working capital.

The gold-bearing intersection is measured along drill core, while true vein widths and economic antimony recovery remain undetermined.

Quarter-end liquidity excludes a US$250 million loan draw and a US$70 million payment due under its amended licensing deal.
The companies accept 101 proposed conditions and modify 13 others, retaining four years of shareholder-funded residential bill credits.
Electrical Americas backlog reached US$16 billion as new manufacturing capacity helped lift its margin from the preceding quarter.
The company confirms federal registrations but does not disclose how many dispensaries received them or identify their locations.
The company allocated US$98.5M of new common-share proceeds to cash while funding preferred buybacks from its general-purpose cash account.
The generator kept its cash-flow and adjusted EBITDA forecasts while raising 2026 sustaining capital spending to C$350M to C$370M.
The Alaska result ended in high-grade mineralization and supports further testing of a possible second gold system at Flat.
Lumentum holders would own about 33 per cent of the combined company, with closing expected in the first half of 2028.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The completed 36,239-metre infill program targets early mining areas, with East Pit assays still expected in the coming months.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The psilocybin developer expects its final application submission within two weeks, with a launch targeted for the first half of 2027.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The September-quarter operating loss included a US$6.2M bitcoin-sale gain, while cash and short-term deposits reached US$39.7M.
Holdings reached 43,124 bitcoin, while additional SATS shares carry US$51,270 in annual cumulative dividends under the stated terms.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The New Jersey utility and nuclear owner kept its 2026 earnings outlook and expects to fund a US$24B to US$28B capital plan without new equity.

The developer is negotiating federal pilot-factory agreements while its first irradiated fuel samples undergo examination in Idaho.

Initial capacity of 1,440 MVA is scheduled for the end of 2029, while the land deal leaves cost and AI customer commitments undisclosed.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The brewer has cut its U.S. footprint to six facilities, while keeping fiscal 2027 adjusted earnings guidance unchanged.

Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.

Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.

The capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.